Skip to main content
Erschienen in: Journal of Neurology 11/2015

01.11.2015 | Original Communication

Influence of glycaemic control on the outcomes of patients treated by intravenous thrombolysis for cerebral ischaemia

verfasst von: Rachel Litke, Solène Moulin, Charlotte Cordonnier, Pierre Fontaine, Didier Leys

Erschienen in: Journal of Neurology | Ausgabe 11/2015

Einloggen, um Zugang zu erhalten

Abstract

Whether the glycaemic control during the first hours of cerebral ischaemia treated by thrombolysis influences outcomes remains unsettled. We aimed at evaluating the quality of the glycaemic control and whether patients with well-controlled glycaemia after thrombolysis for acute cerebral ischaemia have better outcomes. We retrospectively analysed data prospectively collected in consecutive stroke patients who received i.v. thrombolysis at the Lille University Hospital. Patients with glycaemia >1.6 g/l (8.9 mmol/l) at any point during the first 48 h received insulin. We used 2 definitions of well controlled glycaemia: (i) “well controlled 100 %” when 100 % glycaemia were <1.6 g/l (8.9 mmol/l), and (ii) “well controlled 70 %” when at least 70 % glycaemia were <1.6 g/l (8.9 mmol/l). The outcome measures at 3 months were (1) independence [modified Rankin scale (mRS) score 0 or 1], (2) absence of handicap (mRS 0–2), (3) death, and (4) symptomatic intracerebral haemorrhage (sICH). Of 875 consecutive patients, 657 (75.2 %) were considered as well controlled with a threshold at 100 % and 736 (84.2 %) with a threshold at 70 %. The glycaemic control was not independently associated with any of the four outcome measures. In patients treated by insulin, hypoglycaemic events were rare (2.1 % of all patients) and of moderate intensity [>0.5 g/l (2.8 mmol/l)]. The quality of the glycaemic control was not associated with outcomes in patients treated by thrombolysis. A possible explanation is that the glycaemic control after thrombolysis has minor influence compared with glycaemic control before thrombolysis when the artery is not yet re-open and the penumbra area at maximum.
Literatur
1.
Zurück zum Zitat Van Swieten JC, Koudstaal PJ, Visser MC et al (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19:604–607CrossRefPubMed Van Swieten JC, Koudstaal PJ, Visser MC et al (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19:604–607CrossRefPubMed
2.
Zurück zum Zitat The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. New Engl J Med 333:1581–1587CrossRef The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. New Engl J Med 333:1581–1587CrossRef
3.
Zurück zum Zitat Hacke W, Kaste M, Bluhmki E et al (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359:1317–1329CrossRefPubMed Hacke W, Kaste M, Bluhmki E et al (2008) Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359:1317–1329CrossRefPubMed
4.
Zurück zum Zitat Sandercock P, Wardlaw JM, Lindley RI et al (2012) The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 379:2352–2363CrossRefPubMed Sandercock P, Wardlaw JM, Lindley RI et al (2012) The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 379:2352–2363CrossRefPubMed
5.
Zurück zum Zitat Wardlaw JM, Murray V, Berge E et al (2012) Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 379:2364–2372PubMedCentralCrossRefPubMed Wardlaw JM, Murray V, Berge E et al (2012) Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 379:2364–2372PubMedCentralCrossRefPubMed
6.
Zurück zum Zitat Coutinho M, Gerstein HC, Wang Y, Yusuf S (1999) The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22:233–240CrossRefPubMed Coutinho M, Gerstein HC, Wang Y, Yusuf S (1999) The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22:233–240CrossRefPubMed
7.
Zurück zum Zitat Mizock BA (1995) Alterations in carbohydrate metabolism during stress: a review of the literature. Am J Med 98:75–84CrossRefPubMed Mizock BA (1995) Alterations in carbohydrate metabolism during stress: a review of the literature. Am J Med 98:75–84CrossRefPubMed
8.
Zurück zum Zitat Van den Berghe G, Wouters P, Weekers F et al (2001) Intensive insulin therapy in critically ill patients. New Engl J Med 345:1359–1367CrossRefPubMed Van den Berghe G, Wouters P, Weekers F et al (2001) Intensive insulin therapy in critically ill patients. New Engl J Med 345:1359–1367CrossRefPubMed
9.
Zurück zum Zitat Malmberg K, Norhammar A, Wedel H, Rydén L (1999) Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the diabetes and insulin-glucose infusion in acute myocardial infarction. Circulation 99:2626–2632CrossRefPubMed Malmberg K, Norhammar A, Wedel H, Rydén L (1999) Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the diabetes and insulin-glucose infusion in acute myocardial infarction. Circulation 99:2626–2632CrossRefPubMed
10.
Zurück zum Zitat Williams LS, Rotich J, Qi R et al (2002) Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke. Neurology 59:67–71CrossRefPubMed Williams LS, Rotich J, Qi R et al (2002) Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke. Neurology 59:67–71CrossRefPubMed
11.
Zurück zum Zitat Baird TA, Parsons MW, Barber PA et al (2002) The influence of diabetes mellitus and hyperglycaemia on stroke incidence and outcome. J Clin Neurosci 9:618–626CrossRefPubMed Baird TA, Parsons MW, Barber PA et al (2002) The influence of diabetes mellitus and hyperglycaemia on stroke incidence and outcome. J Clin Neurosci 9:618–626CrossRefPubMed
12.
Zurück zum Zitat Capes SE, Hunt D, Malmberg K et al (2001) Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 32:2426–2432CrossRefPubMed Capes SE, Hunt D, Malmberg K et al (2001) Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 32:2426–2432CrossRefPubMed
13.
Zurück zum Zitat Melamed E (1976) Reactive hyperglycaemia in patients with acute stroke. J Neurol Sci 29:267–275CrossRefPubMed Melamed E (1976) Reactive hyperglycaemia in patients with acute stroke. J Neurol Sci 29:267–275CrossRefPubMed
14.
Zurück zum Zitat Desilles JP, Meseguer E, Labreuche J et al (2013) Diabetes mellitus, admission glucose, and outcomes after stroke thrombolysis: a registry and systematic review. Stroke 44:1915–1923CrossRefPubMed Desilles JP, Meseguer E, Labreuche J et al (2013) Diabetes mellitus, admission glucose, and outcomes after stroke thrombolysis: a registry and systematic review. Stroke 44:1915–1923CrossRefPubMed
15.
Zurück zum Zitat Gnofam M, Leys D, Ponchelle-Dequatre N et al (2013) Baseline serum glucose concentration and symptomatic haemorrhagic transformation in non-diabetic stroke patients treated by intravenous thrombolysis. J Neurol 260:2786–2792CrossRefPubMed Gnofam M, Leys D, Ponchelle-Dequatre N et al (2013) Baseline serum glucose concentration and symptomatic haemorrhagic transformation in non-diabetic stroke patients treated by intravenous thrombolysis. J Neurol 260:2786–2792CrossRefPubMed
16.
Zurück zum Zitat Demchuk AM, Morgenstern LB, Krieger DW et al (1999) Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke; a journal of cerebral circulation 30:34–39CrossRefPubMed Demchuk AM, Morgenstern LB, Krieger DW et al (1999) Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke; a journal of cerebral circulation 30:34–39CrossRefPubMed
17.
Zurück zum Zitat Parsons MW, Barber PA, Desmond PM et al (2002) Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study. Ann Neurol 52:20–28CrossRefPubMed Parsons MW, Barber PA, Desmond PM et al (2002) Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study. Ann Neurol 52:20–28CrossRefPubMed
18.
Zurück zum Zitat The European Stroke Organisation (ESO) Executive Committee (2008) Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 25:457–507 (see update at http://www.eso-stroke.org) The European Stroke Organisation (ESO) Executive Committee (2008) Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 25:457–507 (see update at http://​www.​eso-stroke.​org)
19.
Zurück zum Zitat Gray CS, Hildreth AJ, Sandercock PA et al (2007) Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol 6:397–406CrossRefPubMed Gray CS, Hildreth AJ, Sandercock PA et al (2007) Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol 6:397–406CrossRefPubMed
20.
Zurück zum Zitat Bruno A, Kent TA, Coull BM et al (2008) Treatment of hyperglycemia in ischemic stroke (THIS): a randomized pilot trial. Stroke J Cereb Circ 39:384–389CrossRef Bruno A, Kent TA, Coull BM et al (2008) Treatment of hyperglycemia in ischemic stroke (THIS): a randomized pilot trial. Stroke J Cereb Circ 39:384–389CrossRef
21.
Zurück zum Zitat Rosso C, Corvol J-C, Pires C et al (2012) Intensive versus subcutaneous insulin in patients with hyperacute stroke: results from the randomized INSULINFARCT trial. Stroke J Cereb Circ 43:2343–2349CrossRef Rosso C, Corvol J-C, Pires C et al (2012) Intensive versus subcutaneous insulin in patients with hyperacute stroke: results from the randomized INSULINFARCT trial. Stroke J Cereb Circ 43:2343–2349CrossRef
22.
Zurück zum Zitat Jauch EC, Saver JL, Adams HP et al (2013) Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke J Cereb Circ 44:870–947CrossRef Jauch EC, Saver JL, Adams HP et al (2013) Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke J Cereb Circ 44:870–947CrossRef
23.
Zurück zum Zitat Cordonnier C, Girot M, Dorp E et al (2000) Stroke units from scientific evidence to practice: the experience of the Lille stroke unit. Cerebrovasc Dis 10(Suppl 4):17–20CrossRefPubMed Cordonnier C, Girot M, Dorp E et al (2000) Stroke units from scientific evidence to practice: the experience of the Lille stroke unit. Cerebrovasc Dis 10(Suppl 4):17–20CrossRefPubMed
24.
Zurück zum Zitat Bodenant M, Leys D, Debette S et al (2010) Intravenous thrombolysis for acute cerebral ischaemia: comparison of outcomes between patients treated at working versus nonworking hours. Cerebrovasc Dis 30:148–156CrossRefPubMed Bodenant M, Leys D, Debette S et al (2010) Intravenous thrombolysis for acute cerebral ischaemia: comparison of outcomes between patients treated at working versus nonworking hours. Cerebrovasc Dis 30:148–156CrossRefPubMed
25.
Zurück zum Zitat Hacke W, Kaste M, Fieschi C et al (1998) Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 352:1245–1251CrossRefPubMed Hacke W, Kaste M, Fieschi C et al (1998) Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 352:1245–1251CrossRefPubMed
26.
Zurück zum Zitat Lyden P, Brott T, Tilley B et al (1994) Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke 25:2220–2226CrossRefPubMed Lyden P, Brott T, Tilley B et al (1994) Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke 25:2220–2226CrossRefPubMed
27.
Zurück zum Zitat Adams HP Jr, Bendixen BH, Kappelle LJ et al (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24:35–41CrossRefPubMed Adams HP Jr, Bendixen BH, Kappelle LJ et al (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24:35–41CrossRefPubMed
28.
Zurück zum Zitat Bendel RB, Afifi AA (1977) Comparison of stopping rules in forward regression. J Am Stat Ass 72:46–53 Bendel RB, Afifi AA (1977) Comparison of stopping rules in forward regression. J Am Stat Ass 72:46–53
29.
Zurück zum Zitat Glantz SA, Slinker BK (1990) Primer of applied regression and analysis of variance. McGraw Hill, New York Glantz SA, Slinker BK (1990) Primer of applied regression and analysis of variance. McGraw Hill, New York
30.
Zurück zum Zitat Wahlgren N, Ahmed N, Davalos A et al (2007) Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 369:275–282CrossRefPubMed Wahlgren N, Ahmed N, Davalos A et al (2007) Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 369:275–282CrossRefPubMed
31.
Zurück zum Zitat Wahlgren N, Ahmed N, Davalos A et al (2008) Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 372:1303–1309CrossRefPubMed Wahlgren N, Ahmed N, Davalos A et al (2008) Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 372:1303–1309CrossRefPubMed
32.
Zurück zum Zitat Allport L, Baird T, Butcher K et al (2006) Frequency and temporal profile of poststroke hyperglycemia using continuous glucose monitoring. Diabetes Care 29:1839–1844CrossRefPubMed Allport L, Baird T, Butcher K et al (2006) Frequency and temporal profile of poststroke hyperglycemia using continuous glucose monitoring. Diabetes Care 29:1839–1844CrossRefPubMed
33.
Zurück zum Zitat Middleton S, McElduff P, Ward J et al (2011) Implementation of evidence-based treatment protocols to manage fever, hyperglycaemia, and swallowing dysfunction in acute stroke (QASC): a cluster randomised controlled trial. Lancet 378:1699–1706CrossRefPubMed Middleton S, McElduff P, Ward J et al (2011) Implementation of evidence-based treatment protocols to manage fever, hyperglycaemia, and swallowing dysfunction in acute stroke (QASC): a cluster randomised controlled trial. Lancet 378:1699–1706CrossRefPubMed
34.
Zurück zum Zitat Ahmed N, Davalos A, Eriksson N et al (2010) Association of admission blood glucose and outcome in patients treated with intravenous thrombolysis: results from the Safe Implementation of Treatments in Stroke International Stroke Thrombolysis Register (SITS-ISTR). Arch Neurol 67:1123–1130CrossRefPubMed Ahmed N, Davalos A, Eriksson N et al (2010) Association of admission blood glucose and outcome in patients treated with intravenous thrombolysis: results from the Safe Implementation of Treatments in Stroke International Stroke Thrombolysis Register (SITS-ISTR). Arch Neurol 67:1123–1130CrossRefPubMed
35.
Zurück zum Zitat Gerstein HC, Miller ME, Genuth S et al (2011) Long-term effects of intensive glucose lowering on cardiovascular outcomes. New Engl J Med 364:818–828CrossRefPubMed Gerstein HC, Miller ME, Genuth S et al (2011) Long-term effects of intensive glucose lowering on cardiovascular outcomes. New Engl J Med 364:818–828CrossRefPubMed
36.
Zurück zum Zitat Malmberg K, Rydén L, Wedel H et al (2005) Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 26:650–661CrossRefPubMed Malmberg K, Rydén L, Wedel H et al (2005) Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 26:650–661CrossRefPubMed
Metadaten
Titel
Influence of glycaemic control on the outcomes of patients treated by intravenous thrombolysis for cerebral ischaemia
verfasst von
Rachel Litke
Solène Moulin
Charlotte Cordonnier
Pierre Fontaine
Didier Leys
Publikationsdatum
01.11.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 11/2015
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-015-7874-5

Weitere Artikel der Ausgabe 11/2015

Journal of Neurology 11/2015 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.